{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T16:55:58Z","timestamp":1767372958116,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":30,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071631621"},{"type":"electronic","value":"9781071631638"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3163-8_8","type":"book-chapter","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T10:07:13Z","timestamp":1684231633000},"page":"95-121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of Tissue Microarray Profiling and Multiplexed IHC Approaches to Investigate Transport Mechanism of Nucleoside Analog Drug Resistance"],"prefix":"10.1007","author":[{"given":"Debasis","family":"Nayak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna","family":"Weadick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajgopal","family":"Govindarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"8_CR1","first-page":"403","volume-title":"Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine","author":"F Muggia","year":"2012","unstructured":"Muggia F, Diaz I, Peters GJ (2012) Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine, vol 21. Taylor & Francis, pp 403\u2013408"},{"issue":"7","key":"8_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1470-2045(02)00788-X","volume":"3","author":"CM Galmarini","year":"2002","unstructured":"Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3(7):415\u2013424","journal-title":"Lancet Oncol"},{"key":"8_CR3","unstructured":"Pizzorno G, Diasio RB, Cheng Y-C (2003) Pyrimidine analogs. In: Holland-Frei cancer medicine, 6th ed. BC Decker"},{"issue":"3","key":"8_CR4","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/cncr.11935","volume":"100","author":"F Ravandi","year":"2004","unstructured":"Ravandi F, Kantarjian H, Giles F, Cortes J (2004) New agents in acute myeloid leukemia and other myeloid disorders. Cancer 100(3):441\u2013454","journal-title":"Cancer"},{"issue":"5","key":"8_CR5","doi-asserted-by":"publisher","first-page":"a026948","DOI":"10.1101\/cshperspect.a026948","volume":"7","author":"T Sato","year":"2017","unstructured":"Sato T, Issa J-PJ, Kropf P (2017) DNA hypomethylating drugs in cancer therapy. Cold Spring Harb Perspect Med 7(5):a026948","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4\u20136","key":"8_CR6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/15257771003729823","volume":"29","author":"M Molina-Arcas","year":"2010","unstructured":"Molina-Arcas M, Pastor-Anglada M (2010) Role of nucleoside transporters in nucleoside-derived drug sensitivity. Nucleosides Nucleotides Nucleic Acids 29(4\u20136):335\u2013346","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"8_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3389\/fphar.2015.00013","volume":"6","author":"M Pastor-Anglada","year":"2015","unstructured":"Pastor-Anglada M, P\u00e9rez-Torras S (2015) Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets. Front Pharmacol 6:13","journal-title":"Front Pharmacol"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3389\/fonc.2021.650473","volume":"11","author":"C Kordella","year":"2021","unstructured":"Kordella C, Lamprianidou E, Kotsianidis I (2021) Mechanisms of action of hypomethylating agents: endogenous retroelements at the epicenter. Front Oncol 11:490","journal-title":"Front Oncol"},{"issue":"3","key":"8_CR9","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","volume":"113","author":"T Qin","year":"2009","unstructured":"Qin T, Jelinek J, Si J, Shu J, Issa J-PJ (2009) Mechanisms of resistance to 5-aza-2\u2032-deoxycytidine in human cancer cell lines. Blood 113(3):659\u2013667","journal-title":"Blood"},{"issue":"12","key":"8_CR10","doi-asserted-by":"publisher","first-page":"3388","DOI":"10.1038\/s41375-020-0973-z","volume":"34","author":"E Gruber","year":"2020","unstructured":"Gruber E, Franich RL, Shortt J, Johnstone RW, Kats LM (2020) Distinct and overlapping mechanisms of resistance to azacytidine and guadecitabine in acute myeloid leukemia. Leukemia 34(12):3388\u20133392","journal-title":"Leukemia"},{"issue":"10","key":"8_CR11","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1038\/s41388-018-0553-0","volume":"38","author":"Y Jia","year":"2019","unstructured":"Jia Y, Gu D, Wan J, Yu B, Zhang X, Chiorean EG, Wang Y, Xie J (2019) The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. Oncogene 38(10):1764\u20131777","journal-title":"Oncogene"},{"issue":"40","key":"8_CR12","doi-asserted-by":"publisher","first-page":"6844","DOI":"10.3748\/wjg.v27.i40.6844","volume":"27","author":"CJ Carter","year":"2021","unstructured":"Carter CJ, Mekkawy AH, Morris DL (2021) Role of human nucleoside transporters in pancreatic cancer and chemoresistance. World J Gastroenterol 27(40):6844","journal-title":"World J Gastroenterol"},{"issue":"5","key":"8_CR13","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1158\/0008-5472.CAN-10-2736","volume":"71","author":"YD Bhutia","year":"2011","unstructured":"Bhutia YD, Hung SW, Patel B, Lovin D, Govindarajan R (2011) CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. Cancer Res 71(5):1825\u20131835","journal-title":"Cancer Res"},{"key":"8_CR14","doi-asserted-by":"crossref","unstructured":"Voduc D, Kenney C, Nielsen TO (2008) Tissue microarrays in clinical oncology. In: Seminars in radiation oncology, Elsevier. pp 89\u201397","DOI":"10.1016\/j.semradonc.2007.10.006"},{"issue":"4","key":"8_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cac2.12023","volume":"40","author":"WCC Tan","year":"2020","unstructured":"Tan WCC, Nerurkar SN, Cai HY, Ng HHM, Wu D, Wee YTF, Lim JCT, Yeong J, Lim TKH (2020) Overview of multiplex immunohistochemistry\/immunofluorescence techniques in the era of cancer immunotherapy. Cancer Commun 40(4):135\u2013153","journal-title":"Cancer Commun"},{"issue":"2","key":"8_CR16","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/1535-7163.MCT-20-0316","volume":"20","author":"B Weadick","year":"2021","unstructured":"Weadick B, Nayak D, Persaud AK, Hung SW, Raj R, Campbell MJ, Chen W, Li J, Williams TM, Govindarajan R (2021) EMT-induced gemcitabine resistance in pancreatic cancer involves the functional loss of equilibrative nucleoside transporter 1. Mol Cancer Ther 20(2):410\u2013422","journal-title":"Mol Cancer Ther"},{"issue":"5","key":"8_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1634\/theoncologist.2015-0356","volume":"21","author":"G Brandi","year":"2016","unstructured":"Brandi G, Deserti M, Vasuri F, Farioli A, Degiovanni A, Palloni A, Frega G, Barbera MA, Lorenzo S, Garajova I (2016) Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients. Oncologist 21(5):600\u2013607","journal-title":"Oncologist"},{"issue":"10","key":"8_CR18","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1111\/j.1349-7006.2007.00581.x","volume":"98","author":"Y Endo","year":"2007","unstructured":"Endo Y, Obata T, Murata D, Ito M, Sakamoto K, Fukushima M, Yamasaki Y, Yamada Y, Natsume N, Sasaki T (2007) Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides. Cancer Sci 98(10):1633\u20131637","journal-title":"Cancer Sci"},{"key":"8_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00240","volume":"3","author":"LJ Vos","year":"2019","unstructured":"Vos LJ, Yusuf D, Lui A, Abdelaziz Z, Ghosh S, Spratlin JL, Mackey JR (2019) Predictive and prognostic properties of human equilibrative nucleoside transporter 1 expression in gemcitabine-treated pancreatobiliary cancer: a meta-analysis. JCO Precis Oncol 3:1\u201322","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"8_CR20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","volume":"136","author":"JJ Farrell","year":"2009","unstructured":"Farrell JJ, Elsaleh H, Garcia M, Lai R, Ammar A, Regine WF, Abrams R, Benson AB, Macdonald J, Cass CE (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136(1):187\u2013195","journal-title":"Gastroenterology"},{"issue":"3","key":"8_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/bjc.2017.187","volume":"117","author":"B Vincenzi","year":"2017","unstructured":"Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R (2017) Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. Br J Cancer 117(3):340\u2013346","journal-title":"Br J Cancer"},{"issue":"1","key":"8_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1006\/abio.2001.5548","volume":"303","author":"Z Jobbagy","year":"2002","unstructured":"Jobbagy Z, Ward JL, Toan S-V, Leung GP, Tse C-M (2002) One-step unidirectional cloning of tandem repeats of DNA fragments: an application for fusion protein production. Anal Biochem 303(1):104\u2013107","journal-title":"Anal Biochem"},{"issue":"5","key":"8_CR23","first-page":"R1809","volume":"293","author":"R Govindarajan","year":"2007","unstructured":"Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse C-M, Hayashi J, Unadkat JD (2007) In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta. Am J Phys Regul Integr Comp Phys 293(5):R1809\u2013R1822","journal-title":"Am J Phys Regul Integr Comp Phys"},{"issue":"4","key":"8_CR24","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jcmgh.2020.06.009","volume":"10","author":"Y-X Zhu","year":"2020","unstructured":"Zhu Y-X, Li CH, Li G, Feng H, Xia T, Wong CH, Fung FKC, Tong JH-M, To K-F, Chen R (2020) LLGL1 regulates gemcitabine resistance by modulating the ERK-SP1-OSMR pathway in pancreatic ductal adenocarcinoma. Cell Mol Gastroenterol Hepatol 10(4):811\u2013828","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"5","key":"8_CR25","doi-asserted-by":"publisher","first-page":"104193","DOI":"10.1016\/j.isci.2022.104193","volume":"25","author":"D Nayak","year":"2022","unstructured":"Nayak D, Weadick B, Persaud AK, Raj R, Shakya R, Li J, Campbell MJ, Govindarajan R (2022) EMT alterations in the solute carrier landscape uncover SLC22A10\/A15 imposed vulnerabilities in pancreatic cancer. iScience 25(5):104193","journal-title":"iScience"},{"issue":"3","key":"8_CR26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/leu.2013.330","volume":"28","author":"A Valencia","year":"2014","unstructured":"Valencia A, Masala E, Rossi A, Martino A, Sanna A, Buchi F, Canzian F, Cilloni D, Gaidano V, Voso MT (2014) Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia 28(3):621\u2013628","journal-title":"Leukemia"},{"issue":"2","key":"8_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0006-2952(02)01484-3","volume":"65","author":"E M\u00e5nsson","year":"2003","unstructured":"M\u00e5nsson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, Eriksson S, Albertioni F (2003) Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65(2):237\u2013247","journal-title":"Biochem Pharmacol"},{"issue":"15","key":"8_CR28","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0959-8049(00)00246-X","volume":"36","author":"A Bergman","year":"2000","unstructured":"Bergman A, Giaccone G, Van Moorsel C, Mauritz R, Noordhuis P, Pinedo H, Peters G (2000) Cross-resistance in the 2\u2032, 2\u2032-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 36(15):1974\u20131983","journal-title":"Eur J Cancer"},{"issue":"5","key":"8_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s002800050832","volume":"42","author":"N Eliopoulos","year":"1998","unstructured":"Eliopoulos N, Cournoyer D, Momparler RL (1998) Drug resistance to 5-aza-2\u2032-deoxycytidine, 2\u2032, 2\u2032-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42(5):373\u2013378","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"8_CR30","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.leukres.2007.01.018","volume":"31","author":"K Suzuki","year":"2007","unstructured":"Suzuki K, Sugawara T, Oyake T, Uchiyama T, Aoki Y, Tsukushi Y, Onodera S, Ito S, Murai K, Ishida Y (2007) Clinical significance of high-Km 5\u2032-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome. Leuk Res 31(10):1343\u20131349","journal-title":"Leuk Res"}],"container-title":["Methods in Molecular Biology","Cancer Systems and Integrative Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3163-8_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T01:52:34Z","timestamp":1702432354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3163-8_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071631621","9781071631638"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3163-8_8","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"17 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}